Pfizer has agreed to buy Anacor Pharmaceuticals for $5.2 billion – gaining control of an experimental treatment for eczema in its first deal since walking away from a $160 billion takeover of Allergan.
Pfizer will pay $99.25 in cash for each Anacor share, the companies said in a statement today. The transaction, which represents about a 55 per cent premium to Friday’s closing price, is scheduled to be completed in the third quarter and may start adding...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team